TP53 and breast carcinoma: Furthermore, the robust downregulation of p53 expression due to YY2-silencing could also be detected in breast cancer cell line MCF-7 and hepatocarcinoma cell line HepG2 (Supplementary Figure 4B, 4C), suggesting that this regulatory pathway could be found in various tumors.